Independent FDA Panel Recommends Approval of Guardant Health's Blood-Based Colon Cancer Test

May 23, 2024, 06:31 PM

Advisers to the U.S. Food and Drug Administration (FDA) have recommended the approval of Guardant Health's blood-based test for detecting colorectal cancer. If approved, this will be the first blood screening test for colorectal cancer that meets the requirements for Medicare reimbursement. The recommendation by an independent panel marks a significant step towards FDA approval in the U.S., potentially improving early detection and treatment of colon cancer.